Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation
| Autor: | Maria G. Belvisi, Mark A. Birrell, David J Hele |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
medicine.medical_specialty
Pulmonary Fibrosis medicine.medical_treatment Anti-Inflammatory Agents Peroxisome proliferator-activated receptor Inflammation Pharmacology Biology Ligands Pulmonary Disease Chronic Obstructive Lipid biosynthesis Internal medicine medicine Animals Humans Receptor Transcription factor chemistry.chemical_classification Clinical Trials as Topic Prostaglandin D2 Insulin Fatty Acids Asthma PPAR gamma Disease Models Animal Endocrinology Nuclear receptor chemistry Benzimidazoles Thiazolidinediones medicine.symptom Rosiglitazone medicine.drug |
| Zdroj: | European Journal of Pharmacology. 533:101-109 |
| ISSN: | 0014-2999 |
| DOI: | 10.1016/j.ejphar.2005.12.048 |
| Popis: | Peroxisome proliferator-activated receptor gamma (PPARgamma) is a ligand-activated transcription factor belonging to the nuclear hormone receptor superfamily. PPARgamma regulates several metabolic pathways by binding to sequence-specific PPAR response elements in the promoter region of target genes, including lipid biosynthesis and glucose metabolism. Synthetic PPARgamma agonists have been developed, such as the thiazolidinediones rosiglitazone and pioglitazone. These act as insulin sensitizers and are used in the treatment of type 2 diabetes. Recently however, PPARgamma ligands have been implicated as regulators of cellular inflammatory and immune responses. They are thought to exert anti-inflammatory effects by negatively regulating the expression of pro-inflammatory genes. Several studies have demonstrated that PPARgamma ligands possess anti-inflammatory properties and that these properties may prove helpful in the treatment of inflammatory diseases of the airways. This review will outline the anti-inflammatory effects of synthetic and endogenous PPARgamma ligands and discuss their potential therapeutic effects in animal models of inflammatory airway disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect